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Introduction
　The use of core needle biopsy (CNB) specimens collected 
under image guidance has been widely accepted for the di-
agnosis of breast cancer.  Additionally, CNB specimens can 
be used to assess the characteristics of tumors, including 
their lymphovascular invasion, nuclear grading, immuno-
histochemical (IHC) findings (estrogen receptor (ER), pro-
gesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER-2), Ki-67), and so on1, 2.  Histological ob-
servations of CNB are sometimes the only information 
available to determine the therapeutic strategies, i.e., in cas-
es with preoperative systemic therapy.  Especially in pa-
tients with ER+/HER2- tumors, the IHC findings are widely 
used as surrogate markers to classify luminal A and B tu-
mors3.  The problem is whether a small amount of sample 
obtained by CNB reflects the overall histological features of 
the cancers that might have intrinsic heterogeneity.  In order 
to evaluate the pathological reliability of CNB specimens 
for determining the therapeutic strategy for patients with 
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ER+/HER2- invasive breast cancer, we compared the tumor 
biomarker findings, including the lymphovascular invasion, 
nuclear grade, ER, PgR, and Ki67 status in CNB with those 
obtained in the subsequent surgical specimens.
Patients and methods
　We reviewed the clinical and laboratory data of 29 pa-
tients with ER+/HER2- primary invasive breast cancer de-
termined by findings of surgical specimens, who underwent 
CNB and subsequent lumpectomy/mastectomy between 
August 2011 and July 2013 in our department.  Patients were 
excluded if they were treated with systemic or local therapy 
before surgery.  CNBs were performed under ultrasound 
guidance and were taken with an automated biopsy device 
fitted with 14-gauge needles (C. R. Bard, Inc., Covington, 
Georgia, U.S.A).  The median number of CNBs was three 
(range; 2-3), and the median interval between CNB and sur-
gery was 34 days (range; 20-61).  CNB and surgical speci-
mens were fixed in neutral buffered formalin and embedded 
in paraffin before the histopathological analysis.  Fixative 
durations were 4 to 24 hours for the CNB samples and 24 to 
48 hours for the surgical specimens.
Processing of samples
　Five sections were prepared from each paraffin block. 
One slide was stained for hematoxylin and eosin (HE), and 
the remaining slides were kept for IHC staining.  In the IHC 
analysis, sections were incubated with antibodies against 
the ER (clone SP1, Ventana Medical Systems, Inc., AZ, 
USA.), PgR (clone 1E2, Ventana Medical Systems), and Ki-
67 (clone MIB1, DAKO, Tokyo, Japan).  Blots were devel-
oped by the labeled streptavidin biotinylated antibody 
method using automated staining system (BenchMark XT, 
Ventana Medical Systems).
Pathological evaluation
　The histological findings of the surgical specimen were 
taken as the gold standard. Although the existence of lym-
phovascular invasion (ly and v) in cancers was basically 
evaluated by HE staining, Elastica van Gieson staining or 
IHC analysis for anti-D2-40 was performed in the obscure 
cases with HE staining.  The nuclear grading was based on 
the sum of the nuclear atypia score and the mitotic count 
score as follows 4: Grade 1: 2 or 3 points, Grade 2: 4 points, 
Grade 3: 5 or 6 points.  The nuclear atypia score was graded 
from 1 to 3 points according to the variation in the size and 
shape of nuclei and unevenness of chromatin. The mitotic 
counts score was graded from 1 to 3 points, increasing with the 
mitoses in the area in which mitoses were most abundant.  The 
ER- and PgR-positive cell counts were determined by the J-
score as follows 5: J-Score 0: not stained; J-Score 1: stained 
cells <1%; J-Score 2: stained cells ≥ 1% but <10%; J-Score 3a: 
stained cells ≥10% but <50% and ;J-Score 3b: stained cells 
≥50%.  The Ki-67 labeling index (LI) was measured in ap-
proximately 1,000 malignant invasive cells counted in hot spots 
in a high-power field (400×) 6.  The IHC-based surrogate sub-
typing was determined using the following definitions adopted 
by the 2013 St. Gallen Consensus Panel 3: Luminal A-like; ER 
positive / PgR positive (≥ 20%) / HER2 negative / Ki-67<14%, 
Luminal B-like; ER positive / HER2 negative, and at least 
one of: Ki-67 ≥14%, PgR negative or low.
Statistical analysis
　The agreement of the ly, v, nuclear grading and hormonal 
receptors was tested using the kappa test.  The agreement of 
the Ki-67 LI between the results from CNB and those from 
surgical samples were statistically analyzed using Pearsonʼs 
correlation coefficient test.  The results obtained were con-
sidered to be significant at p < 0.05.
Results
Lymphovascular invasion
　Pathological ly and v was identified in the CNB specimen 
in 21 of 29 cases, while the remaining eight CNB samples 
were too little to evaluate these parameters.  The concor-
dance rates for ly and v between CNB and surgical samples 
were only 23.8%, with a kappa value of 0.07 (Table 1) and 
28.6%, with a kappa value of -0.18 (Table 2), respectively. 
In 71.4% of cases, ly was underrated on CNB samples, and 
the v was underdiagnosed in 57.1%.  Notably, ly and v were 
estimated to be absent in 90.5% and 76.2% of cases in CNB 
samples, although the final rates of absence in surgical sam-
ples were only 28.6% and 38.1% respectively.
Nuclear grading
　The nuclear grading was evaluated in 27 cases in both 
CNB and subsequent surgical samples, and there was 63.0% 
(17 out of 27 cases) agreement, with a kappa of 0.41 (Table 
3).  The grading was underrated in 33.3% of the cases, while 
it was overrated in only 3.7% of the cases.
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Estrogen and progesterone receptor status
　Based on the surgical samples, the ER was expressed in 
100% of the cases (Table 4), while PgR was expressed in 
85.7% (24/28) (Table 5).  The concordance rate of the J-score 
was 96.4% (27/28), with a kappa of 0.74, for the ER and was 
82.1% (23/28) for the PgR, with a kappa of 0.68.
Ki-67 labeling index
　The correlation coefficient of the Ki-67 LI between the 
CNB and surgical samples was 0.75 (p<0.001, 95% CI 0.61 
– 1.28) (Figure 1).
CNB
Surgical sample
0 1 2 3 Total
0 5 (83.3%) 8 4 2 19
1 1 0 (0%) 0 0 1
2 0 0 0 (0%) 1 1
3 0 0 0 0 (0%) 0
Total 6 8 4 3 21
Table 1. Lymphatic invasion
 Percentages in parentheses indicate the degree of concordance.
CNB
Surgical sample
0 1 2 3 Total
0 5 (62.5%) 8 3 0 16
1 3 1 (11.1%) 1 0 5
2 0 0 0 (0%) 0 0
3 0 0 0 0 (0%) 0
Total 8 9 4 0 21
Table 2. Vessel invasion
 Percentages in parentheses indicate the degree of concordance.
CNB
Surgical sample
1 2 3 Total
1 12 (92.3%) 0 5 17
2 1 2 (100%) 4 7
3 0 0 3 (25.0%) 3
Total 13 2 12 27
Table 3. Nuclear grading
 Percentages in parentheses indicate the degree of concordance.
CNB
Surgical sample
0 1 2 3a 3b Total
0 0 0 0 0 0 0
1 0 0 0 0 0 0
2 0 0 1 (50.0%) 0 0 1
3a 0 0 1 0 0 1
3b 0 0 0 0 26 (100%) 26
Total 0 0 2 0 26 28
Table 4. Degree of estrogen receptor expression by J-Score
 Percentages in parentheses indicate the degree of concordance.
CNB
Surgical sample
0 1 2 3a 3b Total
0 4 (100%) 0 0 0 0 4
1 0 0 1 0 0 1
2 0 0 0 (0%) 0 0 0
3a 0 0 1 3 (100%) 3 7
3b 0 0 0 0 16 (84.2%) 16
Total 4 0 2 3 19 28
Table 5. Degree of progesteron receptor expression by J-Score
 Percentages in parentheses indicate the degree of concordance.
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Surrogate subtyping
　The concordance rate of the surrogate subtyping based 
on the IHC findings was 82.1% (23 out of 28 cases), with a 
kappa of 0.38 (Table 6).  All five of the remaining cases 
were evaluated as Luminal A-like based on the CNB and 
Luminal B-like based on the corresponding surgical sam-
ples, four of which showed discordance in the Ki-67 LI and 
one in the PgR expression.
Discussion
　Breast cancer is regarded as a systemic disease, and most 
patients require individualized systemic therapy before or 
after surgery, based on the biology of the tumor 3.  Addition-
ally, the most favorable treatment varies depending on the 
progression of the disease. CNB specimens have been wide-
ly used for the diagnosis of breast lesions that can be seen 
under image guidance.  It is sometimes necessary to predict 
the prognosis or determine the therapeutic strategies of the 
patients with primary invasive breast cancer by evaluating 
only CNB samples, for instance, in cases where preopera-
tive systemic therapy has been given, or in cases with ac-
companying metastatic disease.
　Lymphovascular invasion is a prognostic factor 7 or a pre-
dictive factor for loco-regional recurrence in node-negative 
breast cancer 8 and its initial precise evaluation is desirable. 
In this study, ly and v were accurately diagnosed in only 
23.8% and 28.6% of CNB samples, respectively.  Lymphatic 
vessel invasion in invasive breast cancer is seen only in the 
peripheral areas, not in the central areas of tumors in re-
sected specimens 9, and this heterogeneous distribution 
might be one of the reasons for the low accuracy by CNB. 
In early breast cancer patients, a high nuclear grade is as-
sociated with occult metastases and isolated tumor cells in 
non-sentinel lymph nodes 10.  Our concordance rate for nu-
clear grading was 63.0%, and this value was comparable to 
that reported by Badoual et al. and Harris et al 11, 12.  Lym-
phovascular invasion and nuclear grading tended to be un-
derestimated with CNB, as reported previously 13, 14.  In 
terms of the number of CNB, the accuracy of the histologi-
cal grading or hormone receptor status increased with the 
number of CNB passes 15, 16.  This implies that the portions 
sampled and number of passes of CNB are relevant for the 
precise evaluation of the cancer characteristics. 
　One of the purposes of preoperative systemic therapy is 
to permit breast-conserving surgery for patients who would 
otherwise require total mastectomy.  Additionally, preop-
erative systemic therapy can provide information on the 
drug sensitivity, which could be beneficial during the subse-
quent treatment.  Rapidly proliferating tumor subtypes, 
such as the nonluminal HER2 type and triple negative dis-
eases, could subsequently turn into a pCR with systemic 
cytotoxic chemotherapy 3.  Preoperative hormone therapy 
is, in general, carried out for the patients with hormone re-
ceptor-positive breast cancer, for whom chemotherapy is 
unsuitable 17.  ER+/HER2- invasive breast cancer consists of 
heterogeneous entities, and the tumor subtypes vary ac-
cording to the pathological biomarkers, including the de-
gree of ER and PgR expression, nuclear grading and mark-
ers of proliferation such as Ki-67 LI.  In randomized trials 
of preoperative hormone therapy in postmenopausal pa-
tients with ER+ breast cancer, higher ER levels significantly 
correlated with a higher response 18.  On the other hand, the 
degree of expression of the ER and PgR was inversely cor-
related with the response to neoadjuvant chemotherapy 19. 
These reports suggest that the proportion of hormone recep-
tor expression might be more useful to predict the therapeu-
tic efficacy and to determine the therapeutic strategy than a 
dichotomous evaluation of their expression.




















Figure 1. Comparison of the Ki-67 labeling index between CNB 
and surgical specimens (Pearsonʼs correlation coefficient test, cor-
relation coefficient 0.75, p<0.0001).
CNB
Surgical sample
Luminal-A like Luminal-B like Total
Luminal-A like 2 (100%) 5 7
Luminal-B like 0 21 (80.8%) 21
Total 2 26 28
Table 6. Surrogated subtyping
 Percentages in parentheses indicate the degree of concordance.
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　In our study, the proportion of ER and PgR expression 
showed good concordance rates (96.4 and 82.1%, respec-
tively) between CNB and surgical samples, comparable to 
the findings of previous reports.  With respect to prolifera-
tion, hormone therapy and chemotherapy showed similar 
clinical response rates in the patients with a low Ki-67 LI, 
but patients with a high Ki-67 LI had a better response with 
chemotherapy 20. The 2013 St. Gallen Consensus Panel 
strongly endorsed preoperative hormone therapy for post-
menopausal patients with highly positive expression of hor-
mone receptors and disease with a low proliferation rate 3. 
We demonstrated that the Ki-67 LI in CNB was positively 
correlated with that in surgical samples (correlation coeffi-
cient 0.75, p<0.0001).
　In addition to the ER and Ki-67 LI, the PgR expression has 
been considered as the factor that distinguishes Luminal A-
like and Luminal B-like/HER2-negative disease, based on 
the 2013 St. Gallen Consensus Panel.  The concordance rate 
of the surrogate subtyping based on the IHC findings was 
82.1% (23 out of 28 cases) in our study.  The remaining five 
cases showed discordance due to an underestimation of the 
Ki-67 LI or PgR.  The problem with the Ki-67 LI and PgR 
measurement is that it is not standardized among laborato-
ries, and the former is lacking a consensus regarding the 
threshold for the use of adjuvant cytotoxic chemotherapy for 
patients with ER+/HER2- disease 3.  That is why the ready 
availability of multigene molecular assays is expected to help 
provide accurate and reproducible prognostic information 
and prediction of the response to chemotherapy.
　In conclusion, since the ER, PgR and Ki-67 LI, all of 
which are factors defining surrogate subtyping, were well 
correlated between CNB and surgical samples, the appro-
priate systemic therapy could be determined based on the 
findings of CNB specimens.  On the other hand, since the 
lymphovascular invasion and nuclear grading were fre-
quently discordant, their status should be determined based 
on the surgical samples whenever possible.
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